Investigational drugs for hyperuricemia

Bibliography

• Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67(7):960-6
   PubMed Web of Science ®Google Scholar
• Cea Soriano L, Rothenbacher D, Choi HK, et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011;13(2):R39
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63(10):3136-41
   PubMed Web of Science ®Google Scholar
• Smith EU, Diaz-Torne C, Perez-Ruiz F, et al. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 2010;24(6):811-27
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang XM, Wang YL, et al. Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling. J Nephrol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 2008;67:1310-16
   PubMed Web of Science ®Google Scholar
• Choi HK, Atkinson K, Karlson EW, et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005;165(7):742-8
   PubMed Web of Science ®Google Scholar
• Choi JW, Ford ES, Gao X, et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008;59(1):109-16
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012;125(7):679-87. e671
   PubMed Web of Science ®Google Scholar
• Tsumuraya Y, Hirayama T, Tozuka E, et al. Impact of hyperuricemia on the CKD-associated risk factors in a community-based population. Nephrology (Carlton) 2015;20(6):399-404
   PubMed Web of Science ®Google Scholar
• Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13(12):2888-97
   PubMed Web of Science ®Google Scholar
• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008;300(8):924-32
   PubMed Web of Science ®Google Scholar
• Roughley MJ, Belcher J, Mallen CD, et al. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther 2015;17(1):90
   PubMedGoogle Scholar
• Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41(6):1183-90
   PubMed Web of Science ®Google Scholar
• Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38(5):1101-6
   PubMed Web of Science ®Google Scholar
• Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63(1):102-10
   PubMed Web of Science ®Google Scholar
• Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61(7):885-92
   PubMed Web of Science ®Google Scholar
• Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;62(2):170-80
   PubMed Web of Science ®Google Scholar
• Sattui SE, Singh JA, Gaffo AL. Comorbidities in patients with crystal diseases and hyperuricemia. Rheum Dis Clin North Am 2014;40(2):251-78
   PubMed Web of Science ®Google Scholar
• Odden MC, Amadu AR, Smit E, et al. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. Am J Kidney Dis 2014;64(4):550-7
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Alpérovitch A, Aubrun E, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis 2015;74(5):836-42
   PubMed Web of Science ®Google Scholar
• Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010;12(6):223
   PubMed Web of Science ®Google Scholar
• Vinik O, Wechalekar MD, Falzon L, et al. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. J Rheumatol Suppl 2014;92:70-4
   PubMedGoogle Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012; American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64(10):1431-46
   PubMed Web of Science ®Google Scholar
• Yamanaka H; Metabolism JSoGaNA. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 2011;30(12):1018-29
   PubMed Web of Science ®Google Scholar
• Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician 1999;59(7):1799-806
   PubMed Web of Science ®Google Scholar
• Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 2010;22(2):165-72
   PubMed Web of Science ®Google Scholar
• Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med 2013;64:325-37
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1312-24
   PubMed Web of Science ®Google Scholar
• Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007;46(8):1372-4
   PubMed Web of Science ®Google Scholar
• US National Library of Medicine DailyMed: FDA information: allopurinol tablet. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a80fe56f-8d03-423f-8e2a-7ec8c9e5045b [Last accessed on January 2015]
   Google Scholar
• Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs 2011;71(11):1413-39
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353(23):2450-61
   PubMed Web of Science ®Google Scholar
• Jennings CG, Mackenzie IS, Flynn R, et al. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum 2014;44(1):25-30
   PubMed Web of Science ®Google Scholar
• Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58(1):25-32
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102(11):4134-9
   PubMed Web of Science ®Google Scholar
• Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993;27(3):337-43
   PubMed Web of Science ®Google Scholar
• Ryu HJ, Song R, Kim HW, et al. Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol 2013;53(2):211-16
   PubMed Web of Science ®Google Scholar
• Terkeltaub R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther 2009;11(4):236
   PubMed Web of Science ®Google Scholar
• Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009;11(2):135-40
   PubMedGoogle Scholar
• Jick H, Porter JB. Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia. J Clin Pharmacol 1981;21(10):456-8
   PubMed Web of Science ®Google Scholar
• Vaughan LM, Gottehrer A. Effect of xanthine-related compounds on a theophylline assay using theophylline oxidase. Ann Pharmacother 1992;26(12):1576-9
   PubMed Web of Science ®Google Scholar
• Upton RA. Pharmacokinetic interactions between theophylline and other medication (Part I). Clin Pharmacokinet 1991;20(1):66-80
   PubMed Web of Science ®Google Scholar
• Barry M, Feely J. Allopurinol influences aminophenazone elimination. Clin Pharmacokinet 1990;19(2):167-9
   PubMed Web of Science ®Google Scholar
• Pond SM, Graham GG, Wade DN, et al. The effects of allopurinol and clofibrate on the elimination of coumarin anticoagulants in man. Aust N Z J Med 1975;5(4):324-8
   PubMedGoogle Scholar
• Richette P, Flipo RN, Patrikos DK. Characteristics and management of gout patients in Europe: data from a large cohort of patients. Eur Rev Med Pharmacol Sci 2015;19(4):630-9
   PubMed Web of Science ®Google Scholar
• Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 2011;38(9):1957-9
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12(2):R63
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities (CARES). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01101035 [Last updated on: 18 July 2014. Accessed on: 5 May 2015]
   Google Scholar
• Keenan RT. Safety of urate-lowering therapies: managing the risks to gain the benefits. Rheum Dis Clin North Am 2012;38(4):663-80
   PubMed Web of Science ®Google Scholar
• Gandhi PK, Gentry WM, Ma Q, et al. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S payer perspective. J Manag Care Spec Pharm 2015;21(2):165-75
   PubMed Web of Science ®Google Scholar
• Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ 2014;15(5):453-63
   PubMed Web of Science ®Google Scholar
• Grewal HK, Martinez JR, Espinoza LR. Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol 2014;10(5):747-58
   PubMed Web of Science ®Google Scholar
• Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417(6887):447-52
   PubMed Web of Science ®Google Scholar
• Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008;283(40):26834-8
   PubMed Web of Science ®Google Scholar
• Caulfield MJ, Munroe PB, O’Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008;5(10):e197
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Hernandez-Baldizon S, Herrero-Beites AM, et al. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout. Arthritis Care Res (Hoboken) 2010;62(9):1299-305
   PubMed Web of Science ®Google Scholar
• Hisatome I, Tanaka Y, Kotake H, et al. Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+. Na(+)-citrate. Nephron 1993;65(4):578-82
   PubMedGoogle Scholar
• Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008;31(8):643-65
   PubMed Web of Science ®Google Scholar
• Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306(7):711-20
   PubMed Web of Science ®Google Scholar
• Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60(1):59-68
   PubMed Web of Science ®Google Scholar
• NICE. Pegloticase for the treatment of hyperuricaemia in people with symptomatic gout whose disease is refractory to conventional urate-lowering therapy, or in whom conventional urate-lowering therapy is contraindicated or not tolerated. Available from: http://www.nice.org.uk/guidance/ta291/documents/gout-chronic-refractory-pegloticase-2nd-line-uk-gout-society2
   Google Scholar
• Pegloticase for the treatment of hyperuricaemia in people with symptomatic gout symptomatic gout whose disease is refractory to conventional urate- lowering therapy, or in whom conventional urate-lowering therapy is contraindicated or not tolerated. 2012. Available from: http://www.nice.org.uk/guidance/ta291/documents/gout-chronic-refractory-pegloticase-2nd-line-evidence-review-group-report2 http://www.nice.org.uk/guidance/ta291/documents/gout-chronic-refractory-pegloticase-2nd-line-savient-pharmaceuticals2
   Google Scholar
• Moolenburgh JD, Reinders MK, Jansen TL. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 2006;25(5):749-52
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Yadav H, Vaidya R, et al. Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. Am J Hematol 2013;88(2):152-4
   PubMed Web of Science ®Google Scholar
• Allen KC, Champlain AH, Cotliar JA, et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf 2015;38(2):183-7
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11(2):R46
   PubMed Web of Science ®Google Scholar
• Choi Y-J, Vanina L, Lucman A, et al. Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties [abstract]. Arthritis Rheum 2012;64(Suppl 10):1632
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther 2014;36(10):1465-79
   PubMed Web of Science ®Google Scholar
• CymaBay Therapeutics, Inc. (Amendment No. 2). Available from: http://www.sec.gov/Archives/edgar/data/1042074/000119312513401450/d569374d1012ga.htm
   Google Scholar
• Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat. Available from: http://ir.cymabay.com/press-releases/detail/234/ [Last released on 12 January 2015. Accessed on 5 May 2015]
   Google Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-74
   PubMed Web of Science ®Google Scholar
• Yeh L, Shen Z, Kerr B. RDEA594: a potent URAT1 inhibitor without affecting other important renal transporters, OAT1 and OAT 3 [abstract]. Ann Rheum Dis 2009;68:320
   Google Scholar
• Ardea Biosciences Announces positive results from a Phase 1 Study of RDEA594. Medical News Today. 2009. Avaialble from http://www.medicalnewstoday.com/articles/135285.php [Last accessed 5 May 2015]
   Google Scholar
• Perez-Ruiz F, Sundy J, Krishnan E, et al. Efficacy and safety of lesinurad (RDEA 594), A novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: Randomzied, Double-blind, Plcaebo-controlled, Phase 2B study. Arthritis Rheum 2011;63(Suppl 10):1021
   PubMedGoogle Scholar
• Perez-Ruiz F, Sundy J, Krishnan E, et al. Efficacy and Safety of Lesinurad (RDEA 594), A novel URAT1 inhibitor, in combination with allopurinol in allopurinol-refractory gout patients: Randomzied, Double-blind, Plcaebo-controlled, Phase 2B extension study. 2011
   Google Scholar
• Fleischmann R, Kerr B, Yeh LT, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford) 2014;53(12):2167-74
   PubMed Web of Science ®Google Scholar
• Harrold L. New developments in gout. Curr Opin Rheumatol 2013;25(3):304-9
   PubMed Web of Science ®Google Scholar
• Tan PK, Hyndman D, Liu S, et al. Lesinurad (RDEA594), a novel investigationaluricosuric agent for hyperuricemia and gout, blocks transport of uricacid induced by hydrochlorothiazide [abstract]. Ann Rheum Dis 2011;70(Suppl 3):187
   Google Scholar
• Diaz-Torné C, Perez-Herrero N, Perez-Ruiz F. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol 2015;27(2):164-9
   PubMed Web of Science ®Google Scholar
• Miner JN, Tan P. RDEA3170, A novel, high affinity URAT1 inhibitor binds to central domain within URAT1. Ann Rheum Dis 2012;71(Suppl 3):446
   Google Scholar
• Ardea Biosciences,Inc. Ardea Biosciences provides additional positive clinical results for lesinurad and initial clinical results for RDEA3170 at the 2011 ACR/ARHP Annual Scientific Meeting. Available from: http://www.ardeabio.com/assets/001/5189.pdf
   Google Scholar
• Clinicaltrials.gov. RDEA3170 and feboxostat combination study in subjects with gout. Available from: https://clinicaltrials.gov/ct2/show/NCT02246673
   Google Scholar
• Clinicaltrials.gov. RDEA3170 and allopurinol combination study in gout subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT02279641
   Google Scholar
• Mandai A, Emerling D, Serafini T, et al. Traniiast inhibits urate transport mediated by URATl and GLUT9 [abstract]. 74th Annual Scientific Meeting of the American College of Rheumatology. 2010 Nov 7-11; Atlanta (GA). Arthritis Rheum 2010;62(Suppl 10):164
   Google Scholar
• Sundy JS, Kitt M. Traniiast, a novel, potential treatment for the chronic management of hyperuricemia In patients with gout, reduces serum uric acid (SUA) in healthy subjects [abstract]. Ann Rheum Dis 2010;69(Suppl 3):607
   Google Scholar
• Nuon Therapeutics, Inc. Traniiast plus allopurinol in patients with moderate to severe gout (TAnGO) [ClinicalTrials.gov identifier NCTOI109121]. US National Institutes of Health. CliniailTrials.gov [online]. Available from URL http://www.clinicaltrials.gov [Last accessed on 27 Jun 2011]
   Google Scholar
• Noveck RJ, Zongyao WZ, Forsthoefel KS, et al. Levotofisopam has uricosuric activityand reduces serum urate levels in patients with gout. Arthritis Rheum 2012;64(Suppl 10):S356
   Web of Science ®Google Scholar
• Ahn SO, Horiba N, Ohtomo S, et al. The therapeutic efficacy of the noveluricosuric agent UR-1102 for hyperuricemia and gout. Ann Rheum Dis 2013;72(Suppl 3):704
   Google Scholar
• Fitz-Patrick D, Drummond W, Pappas J, et al. Effects of a purine nucieoside phosphorylase inhibitor, BCX4208, on the. serum uric acid concentrations in patients with gout. 74th Annual Scientific Meeting of the American College of Rheumatology, 2010 Nov 7-11; Atlanta (GA). Arthritis Rheum 2010;62(Suppl 10):150
   PubMedGoogle Scholar
• Becker MA, Hollister AS. Terkeltaub R, et al. BCX4208 combined with allopurinol increases response rates in patients with gout Who fail to reach goal range serum urate on allopurinol alone: A Randomized, Double-Blind, Placebo-Controlled Trial. [late-breaking abstract]. 2011
   Google Scholar
• Hollister AS, Maetzel A, Becker MA, et al. Ulodesine (BCX4208) long-term safety when added to allopurinol in the chronic management of gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study [abstract]. Arthritis Rheum 2012;64(Suppl 10):150
   Google Scholar
• Bantia S, Harman L, Hollister A, et al. [FRI0401] BCX4208, A Novel enzyme inhibitor for chronic managment of gout, shows a low risk of potential drug-drug interactions. Ann Rheum Dis 2012;71:(Suppl3):450
   Google Scholar
• Grunebaum E, Cohen A, Roifman CM. Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Curr Opin Allergy Clin Immunol 2013;13(6):630-8
   PubMed Web of Science ®Google Scholar
• TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan. 2014. Available from: http://www.prnewswire.com/news-releases/twi-biotechnology-receives-approval-of-protocol-for-its-drug-ac-201-controlled-release-tablet-phase-ii-clinical-trial-in-both-the-united-states-and-taiwan-300008980.html
   Google Scholar
• Available from: Clinicaltrials.gov
   Google Scholar